A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of the Combination of AEGR-733 (Formerly BMS201038) [lomitapide] and Atorvastatin 20 mg vs. Monotherapy in Subjects With Moderate Hypercholesterolemia.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of the Combination of AEGR-733 (Formerly BMS201038) [lomitapide] and Atorvastatin 20 mg vs. Monotherapy in Subjects With Moderate Hypercholesterolemia.

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Feb 2013

At a glance

  • Drugs Lomitapide (Primary) ; Atorvastatin
  • Indications Hypercholesterolaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Jun 2009 Final results presented at the American Diabetes Association's 69th Scientific Sessions (7 June) and the International Symposium on Atherosclerosis (15 Jun).
    • 09 Oct 2008 Actual end date changed from Aug 2008 to Oct 2008 as reported by Clinicaltrials.gov.
    • 09 Oct 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top